The Food and Drug Administration has approved a cheaper generic version of the allergy drug EpiPen, which was the subject of intense public scrutiny a few years ago due to its $600 price tag for a two-pack.
The agency said on Thursday that the move was part of an effort to speed up approval of more complex generic products in order to lower prices.
Real journalism.Trusted by millions.
Unlimited access to in-depth reporting, expert analysis, and the stories that shape our country.
Subscribe Now
Already a member? Log in
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.